Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BRAF D594G |
| Therapy | Cetuximab + Trametinib |
| Indication/Tumor Type | colon carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF D594G | colon carcinoma | predicted - sensitive | Cetuximab + Trametinib | Case Reports/Case Series | Actionable | In a clinical case study, treatment with the combination of Erbitux (cetuximab) and Mekinist (trametinib) resulted in a radiologic complete response after 6 months in a patient with colon carcinoma harboring BRAF D594G (PMID: 39516363). | 39516363 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (39516363) | Therapeutic vulnerabilities and pan-cancer landscape of BRAF class III mutations in epithelial solid tumors. | Full reference... |